EHA Library - The official digital education library of European Hematology Association (EHA)

This abstract is embargoed until Friday, June 14, 2024 (09:00 CEST).

Presentation during EHA2024: All Oral presentations will be presented between Friday, June 14, 2024 and Sunday, June 16, 2024 and will be accessible for on-demand viewing from Wednesday, June 19 until Thursday, August 15, 2024 on the Congress platform.

Abstract: S210

Title: CEVOSTAMAB IN PATIENTS WITH RRMM WHO ARE TRIPLE-CLASS REFRACTORY AND HAVE RECEIVED A PRIOR BCMA-TARGETED ADC OR CAR T-CELL: INITIAL RESULTS FROM THE PHASE I/II CAMMA 2 STUDY


Abstract Type: Oral Presentation

Keywords: Multiple myeloma | Antibody | Bispecific | relapsed/refractory
This abstract is embargoed until Friday, June 14, 2024 (09:00 CEST).

Presentation during EHA2024: All Oral presentations will be presented between Friday, June 14, 2024 and Sunday, June 16, 2024 and will be accessible for on-demand viewing from Wednesday, June 19 until Thursday, August 15, 2024 on the Congress platform.

Abstract: S210

Title: CEVOSTAMAB IN PATIENTS WITH RRMM WHO ARE TRIPLE-CLASS REFRACTORY AND HAVE RECEIVED A PRIOR BCMA-TARGETED ADC OR CAR T-CELL: INITIAL RESULTS FROM THE PHASE I/II CAMMA 2 STUDY


Abstract Type: Oral Presentation

Keywords: Multiple myeloma | Antibody | Bispecific | relapsed/refractory
CEVOSTAMAB IN PATIENTS WITH RRMM WHO ARE TRIPLE-CLASS REFRACTORY AND HAVE RECEIVED A PRIOR BCMA-TARGETED ADC OR CAR T-CELL: INITIAL RESULTS FROM THE PHASE I/II CAMMA 2 STUDY
Shaji Kumar
Shaji Kumar
Author(s): Shaji Kumar,  
Shaji Kumar
Affiliations:
Mayo Clinic, Rochester, MN, United States of America
Jesus Berdeja,  
Jesus Berdeja
Affiliations:
Tennessee Oncology and Sarah Cannon Research Institute, Nashville, TN, United States of America
Douglas Sborov,  
Douglas Sborov
Affiliations:
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States of America
Paolo Corradini,  
Paolo Corradini
Affiliations:
Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milano, Milan, Italy
Yael Cohen,  
Yael Cohen
Affiliations:
Sourasky Medical Center and Tel Aviv University, Tel Aviv, Israel
Alexander Lesokhin,  
Alexander Lesokhin
Affiliations:
Memorial Sloan Kettering Cancer Center, New York, NY, United States of America
Moshe Gatt,  
Moshe Gatt
Affiliations:
Hadassah Medical Center and Hebrew University of Jerusalem, Jerusalem, Israel
Laura Paris,  
Laura Paris
Affiliations:
Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Milan, Italy
Laura Rosiñol,  
Laura Rosiñol
Affiliations:
Hospital Clinic de Barcelona and Insitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Hang Quach,  
Hang Quach
Affiliations:
St Vincent’s Hospital Melbourne and University of Melbourne, Melbourne, VIC, Australia
Joshua Richter,  
Joshua Richter
Affiliations:
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America
Ameet Mishra,  
Ameet Mishra
Affiliations:
Genentech, Inc., South San Francisco, CA, United States of America
Oliver Catalani,  
Oliver Catalani
Affiliations:
F. Hoffmann-La Roche Ltd, Basel, Switzerland
Katerina Chineneyze,  
Katerina Chineneyze
Affiliations:
Roche Products Ltd, Welwyn, United Kingdom
Paresh Sewpaul,  
Paresh Sewpaul
Affiliations:
Roche Products Ltd, Welwyn, United Kingdom
Elisabeth Wassner Fritsch,  
Elisabeth Wassner Fritsch
Affiliations:
F. Hoffmann-La Roche Ltd, Basel, Switzerland
Michel Delforge
Michel Delforge
Affiliations:
Universitair Ziekenhuis (UZ) Leuven, Leuven, Belgium
(Abstract release date: 05/14/24) EHA Library. Kumar S. 06/13/2024; 422314; S210
This abstract is embargoed until Friday, June 14, 2024 (09:00 CEST).

Presentation during EHA2024: All Oral presentations will be presented between Friday, June 14, 2024 and Sunday, June 16, 2024 and will be accessible for on-demand viewing from Wednesday, June 19 until Thursday, August 15, 2024 on the Congress platform.

Abstract: S210

Title: CEVOSTAMAB IN PATIENTS WITH RRMM WHO ARE TRIPLE-CLASS REFRACTORY AND HAVE RECEIVED A PRIOR BCMA-TARGETED ADC OR CAR T-CELL: INITIAL RESULTS FROM THE PHASE I/II CAMMA 2 STUDY


Abstract Type: Oral Presentation

Keywords: Multiple myeloma | Antibody | Bispecific | relapsed/refractory
This abstract is embargoed until Friday, June 14, 2024 (09:00 CEST).

Presentation during EHA2024: All Oral presentations will be presented between Friday, June 14, 2024 and Sunday, June 16, 2024 and will be accessible for on-demand viewing from Wednesday, June 19 until Thursday, August 15, 2024 on the Congress platform.

Abstract: S210

Title: CEVOSTAMAB IN PATIENTS WITH RRMM WHO ARE TRIPLE-CLASS REFRACTORY AND HAVE RECEIVED A PRIOR BCMA-TARGETED ADC OR CAR T-CELL: INITIAL RESULTS FROM THE PHASE I/II CAMMA 2 STUDY


Abstract Type: Oral Presentation

Keywords: Multiple myeloma | Antibody | Bispecific | relapsed/refractory

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies